2025 NET Cancer Day Symposium Speakers

Taymeyah Al-Toubah, MPH, CCRP

FlaNET, Medical Student

I hold dual bachelor’s degrees in Biomedical Sciences and Psychology (2015) and a Master of Public Health in Epidemiology (2017). Since 2013, I have worked in academic medicine and clinical research, beginning with neonatology and pediatrics before transitioning to phase I oncology in 2016. My interest in neuroendocrine tumors (NETs) began during my MPH thesis, which became one of my first NET publications.

From 2018–2023, I served as the primary NET coordinator at Moffitt Cancer Center, managing all clinical trials, leading the GI team, and driving retrospective and non-interventional research. In 2023, I transitioned to Senior Project Manager of the NET program, overseeing protocol development, database creation, and manuscript writing, while curating a master database of more than 10,000 NET patients. After nearly a decade at Moffitt, I concluded my tenure in September 2025 to begin medical school in Italy the following month.

I have published more than 45 manuscripts and delivered oral presentations at both ENETS and NANETS. Beyond institutional research, I serve on the Board of Directors of NANETS (now in my second year) and on the board of FLaNET Carcinoid Community. I also actively mentor three students in neuroendocrine tumor research: two undergraduate pre-medical students and a high school prodigy pursuing mathematical oncology and AI. In July 2025, I launched TayTalks, a podcast exploring professional growth, medicine, and life.

Looking ahead, I am eager to combine my research foundation, medical training, and passion for advocacy to advance the care of NET patients as a future physician-scientist.

Aman Chauhan, MD

Medical Oncologist

Sylvester Comprehensive Cancer Center

Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects.

His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee.

Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society.

Tracy Crane, PhD, RDN

Medical Oncology

Sylvester Cancer Center

Dr. Tracy E. Crane is an internationally recognized thought leader in cancer prevention and control, specializing in digital health interventions to improve patient outcomes. She is an Associate Professor of Medical Oncology, Public Health, and Kinesiology at the University of Miami and Co-Leader of the Cancer Control Research Program at Sylvester Comprehensive Cancer Center. 

As Director of Lifestyle Medicine, Prevention, and Digital Health, she leads a multidisciplinary research team focused on innovative lifestyle interventions, leveraging AI-driven technology to deliver precision behavioral strategies. In the last 5 years, she has secured over $30 million in research funding, including multiple National Cancer Institute (NCI)-funded studies and a large PCORI-funded trial, and has authored over 100 peer-reviewed publications, including co-authoring the latest American Cancer Society guidelines on nutrition and physical activity for cancer survivors. 

A registered dietitian with a Ph.D. in Nursing Science, Dr. Crane also serves as Chair for Cancer Prevention and Control nationally for NRG Oncology’s NCI Community Oncology Research Program. Her pioneering contributions have made her a sought-after speaker and leader in the global effort to integrate digital health and personalized lifestyle medicine into cancer prevention and care.

Jashodeep Datta, MD

Surgical Oncologist

Sylvester Comprehensive Cancer Center

Dr. Datta is the DiMare Family Endowed Chair in Immunotherapy, Associate Professor of Surgery, and a hepatobiliary and pancreatic surgical oncologist at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. He is also a surgeon-scientist studying myeloid immunobiology in the pancreatic cancer microenvironment and novel ways to deploy immunotherapy in this disease. At Sylvester, he serves as the Assistant Director of Transdisciplinary Research, and Co-Leader of the Gastrointestinal Oncology Service Line at Sylvester where his mission is to augment the portfolio of investigator-initiated clinical trials offered in GI cancers. He is also the Associate Director of Translational Research at the Sylvester Pancreatic Cancer Research Institute.

Dr. Datta joined the faculty at the University of Miami Miller School of Medicine in 2019. He graduated Summa cum Laude from Colgate University in Hamilton, NY and attended Vanderbilt University School of Medicine in Nashville, TN where he earned his MD and was inducted in the Alpha Omega Alpha (AOA) National Honor Society. He completed his residency in General Surgery at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, during which he completed a post-doctoral research fellowship in cancer immunology. He subsequently completed a fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he focused on surgical management of hepatobiliary, pancreatic, and gastric malignancies and developed expertise in computational immunogenomics.

Since starting at Sylvester, his research has been extensively funded by the Miami Clinical and Translational Science Institute with an NIH KL2 award, American College of Surgeons’ Franklin H. Martin Research Fellowship, Association for Academic Surgery Joel J. Roslyn Faculty Award, Society for Surgical Oncology Young Investigator Award, the Elsa U. Pardee Foundation, the Pancreatic Cancer Action Network Career Development Award, the Department of Defense Pancreatic Cancer Research Program (PCARP), the V Foundation for Cancer Research, and the National Cancer Institute. His work has been recognized by multiple awards, including the Joan L and Julius H Jacobson II Promising Investigator Award from the American College of Surgeons, and an American Society of Clinical Investigation Young-Physician Scientist Award.

Udhayvir Singh Grewal, MD

Medical Oncologist

Emory University School of Medicine

Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. 

After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team.

Boris Naraev, MD, PhD, FACP

Medical Oncologist

Tampa General Hospital Cancer Institute

Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute  specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate  Professor of Medicine at the Division of Hematology and Medical Oncology of University of South  Florida, Morsani College of Medicine.  

Prior to joining the TGH Cancer Institute, he was the Lead of Neuroendocrine Cancer Program at Banner  MD Anderson Cancer Center in Phoenix, Arizona and Adjunct Assistant Professor with the Department of  Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston,  Texas. While in Phoenix, he helped create, develop, and lead one of the largest neuroendocrine cancer  programs in the Southwestern United States, and was personally taking care of a large population of  patients with neuroendocrine tumors.  

Later, he served as the Leader of Gastrointestinal, Neuroendocrine, and Rare Cancers Program at the  Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In this capacity, he helped  build the National Pancreas Foundation Pancreatic Cancer Center of Excellence at Jupiter Medical Center.  

He received his Doctor of Medicine degree from Orenburg State Medical Academy in Orenburg, Russia.  Subsequently, he obtained PhD in Medical Sciences degree from the same institution. After completion  of Internal Medicine residency training at St. Luke's Hospital in Chesterfield, Missouri, he proceeded to  complete Hematology/Oncology Fellowship at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. During his fellowship training, he developed a special interest in neuroendocrine tumors and  completed several research projects in this field.  

Dr. Naraev is involved in neuroendocrine tumors related research and community outreach, and is a  member of the NETPact Committee and Co-Chair of Guidelines Committee of the North American  Neuroendocrine Tumor Society.

Estelamari Rodriquez, MD, MPH

Clinical Research Lead Thoracic Site Disease Group

Associate Director for Community Outreach

Sylvester Cancer Center

Dr. Estelamari Rodriguez is Co-Lead of the Thoracic Site Disease Group and Associate Director of Community Outreach and of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.  She is an active member of the Sylvester Experimental Therapeutics Program and has served as principal investigator of several early phase and cooperative group clinical trials in the United States.

Dr. Rodriguez is a member of the ECOG Thoracic Committee and Chair-elect of the ASCO Evidence Based Medicine Committee. She has active advocacy roles as part of the board of the American Cancer Society- Cancer Action Network, the Miami Dade County Medical Association and Florida Society of Clinical Oncology (FLASCO).

Dr. Rodriguez received her bachelor's degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous international lectures as an invited speaker on issues related to lung cancer treatment and healthcare disparities. 

Jason Starr, DO

Hematologist / Oncologist

Mayo Clinic

Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship.

Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology.

"The greatest joy of my career is the interaction and relationships I am able to have with my patients," says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief.

Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic's conviction to hope, faith, and science.

Lindsay Thornton, MD

Interventional Radiologist

Sylvester Cancer Center

Dr. Lindsay Thornton, M.D., is an Assistant Professor of Clinical Interventional Radiology at the University of Miami Miller School of Medicine. She specializes in interventional oncology, with a focus on hepatocellular carcinoma (HCC), metastatic colorectal cancer, neuroendocrine cancer, and uveal melanoma. She is highly skilled in transradial techniques for liver cancer treatments, uterine fibroid therapy, and other intra-arterial procedures.

Dr. Thornton earned her medical degree from the University of Vermont, followed by an Internal Medicine internship at Rutgers-University Hospital. She then completed her Diagnostic Radiology residency at the University of Florida, where she served as Chief Resident of Research. She also was elected Clinical Education Chair for the Society of Interventional Radiology’s (SIR) RFS section from 2016-2017. She received the Excellence in Interventional Radiology Award in 2018 from UF and went on to complete her fellowship in Vascular and Interventional Radiology at Mount Sinai Icahn School of Medicine in 2019. She is board-certified in both Diagnostic and Interventional Radiology.

Passionate about the disease process and treatment of HCC and clinical research, Dr. Thornton primarily studies locoregional therapies for HCC and co-chairs the Hepatocellular Operations Working Group with Dr. Patricia Jones since 2019. She has published in peer-reviewed journals and presented at national conferences. She also serves on the Interventional Oncology Service Line Committee for SIR (2023-current).

An ardent advocate for quality, safety, and process improvement, Dr. Thornton is committed to enhancing patient care and streamlining clinical workflows. Her joy as a physician stems from ensuring high quality, personal care. She has served as Director of Quality, Safety, and Operations in Interventional Radiology at Jackson Memorial Hospital for the past three years. In 2023 she received the UM/JHS Quality and Safety Faculty Showcase Award.